AbbVie released its 2018 financial report on Jan. 25, 2019, according to which, the 2018 sales of Humira reached USD19.936 billion, securing its position as the global drug king and topping for seven times in terms of sales!

Humira: AbbVie has reached settlements with many companies

As the first fully human monoclonal antibody marketed, Humira (adalimumab) has been marketed in major regions of the world with a total of 14 indications, since marketed in 2002.

Marketed for 16 years, AbbVie’s Humira has gradually become a super-blockbuster and replaced Lipitor to top as the global drug king for 7 consecutive years, accumulatively bringing USD132.878 billion sales revenue to AbbVie.

Many manufacturers are eying Humira that props up AbbVie as a super-blockbuster. So far, AbbVie has reached patent settlements with 9 manufacturers (as shown in the following table). Humira will continue its myth for years, however, it will eventually be impacted by biosimilars and its sales will gradually decline.

Biosimilar patent settlements and expected marketing time